LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Quantitative Testing System for Coronavirus Detection Could Also Diagnose Other Viral Illnesses

By LabMedica International staff writers
Posted on 25 Sep 2024
Print article
Image: The Express Biochecker and measurement results of N protein concentrations for novel coronavirus (CoV-2, yellow) and a different coronavirus (229E, blue) (Photo courtesy of Hiroshi Yabu)
Image: The Express Biochecker and measurement results of N protein concentrations for novel coronavirus (CoV-2, yellow) and a different coronavirus (229E, blue) (Photo courtesy of Hiroshi Yabu)

The COVID-19 pandemic highlighted the critical role of disease testing. Over the past few years, most people have undergone PCR (Polymerase Chain Reaction) or ELISA (Enzyme-Linked Immunosorbent Assay) tests. However, these methods have limitations, requiring large sample volumes, complex procedures, and even presenting risks of exposing testers to the virus. Now, a team of researchers has developed a new quantitative testing system that offers a simpler, faster, and more cost-effective way to detect the coronavirus N protein. This advanced microfluidic technology-based system is not limited to coronavirus detection and is expected to be applicable to other viral illnesses such as influenza and hepatitis in the future.

This novel immunoassay system called the "Express Biochecker" was developed by scientists at Tohoku University (Sendai, Japan) and is based on Janus particles. These particles, named after the two-faced Roman god Janus, feature two distinct sides: one coated with a fluorescent dye and the other with magnetic particles and antibodies. These particles are designed to specifically bind to target antigens, such as viral proteins, and are used with antibody-immobilized microfluidic devices for precise measurement.

The versatility of this system is a major advantage. It not only enables the detection of viruses in various diseases but also has the potential to be adapted for measuring other biomarkers linked to different health conditions. This adaptability could lead to new opportunities in medical diagnostics. Future research will aim to extend the system's capabilities to detect additional disease markers. The findings were detailed in the journal Langmuir.

Related Links:
Tohoku University

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
Ross River Virus Test
Ross River Virus Real Time PCR Kit

Print article

Channels

Sekisui Diagnostics UK Ltd.